The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC).
 
Jose A. Karam
Stock and Other Ownership Interests - Alimera Sciences; MedTek
Honoraria - Pfizer; Roche/Genentech
Consulting or Advisory Role - Pfizer; Roche/Genentech
Research Funding - Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Surena F. Matin
Honoraria - Taris BioMedical; Urogen pharma
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; QED Therapeutics; Taris BioMedical; Urogen pharma
Research Funding - AT&T; Specialized Program in Oncology Research (SPORE)
Travel, Accommodations, Expenses - MSD
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Amado J. Zurita
Honoraria - Exelixis; Janssen Oncology; Pfizer
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; OncoCyte; Pfizer
Speakers' Bureau - MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Cara L. Haymaker
Research Funding - Idera (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst)
 
Enrica Marmonti
No Relationships to Disclose
 
Dzifa Yawa Duose
No Relationships to Disclose
 
Edwin R. Parra
No Relationships to Disclose
 
Luisa Maren Solis
No Relationships to Disclose
 
Caddie Laberiano
No Relationships to Disclose
 
Marisa Lozano
No Relationships to Disclose
 
Alice Abraham
No Relationships to Disclose
 
Max Hallin
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Peter Olson
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology
 
Christopher G. Wood
No Relationships to Disclose